Poly Medicure Limited · NSE:POLYMED
Poly Medicure — Q3 FY25 Earnings Presentation
19 slides from Poly Medicure's earnings presentation, Feb 3, 2025
Slide 1: Exchange submission cover letter
Poly Medicure Limited Regd . Office· 232 B, 3rd Floor, Okhla Industrial Estate, Phase- Ill, New Delhi - 110 020 (INDIA) ·,' IPOLYMED ~+91 - ll - 33550700,47317000 E: in fo@polymedicure com W: polymedicure.com CIN : L 40300DL l 995PLC066923 Date: 03 rd February 2025 Scrip Code: - 531768 Scrip Code:-
Slide 2: Investor Presentation – Q3 and 9M FY 25 Results
Investor Presentation – Q3 and 9M FY 25 Results 3rd February 2025
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Poly Medicure Limited (the "Company"), content of which was compiled from sources believed to be reliable for informational purposes only and are based on information regarding the Company and the economic, regulatory, market and other conditions as
Slide 4: Agenda
Agenda Agenda Slide # Polymed Overview and Way Forward 5-8 YoY Performance Summary Q3 FY 25 and 9M 10 - 11 Key Updates for the Quarter 12 Consolidated and Standalone Financial Performance Summary 13 - 14 Sales Performance Analysis 15-16 Return Ratios Basis Standalone Financials 17
Slide 5: Polymed Overview and Way Forward
Agenda Polymed Overview and Way Forward
Slide 6: Polymed Key Differentiators
Polymed Key Differentiators § Legacy – Operating since 1997 § Leadership – Among the top five medical device industry companies in India by operating income (Source: CRISIL) § Focus on innovation : Granted 334 patents in India and globally § Manufacturing powerhouse – Backward integrated manufacturi
Slide 7: Polymed at a Glance
Polymed at a Glance 12 12 Manufacturing Plants Specialities Across 4 countries 125+ Countries 200+ Medical Devices 3000+ Employee Base 475+ Sales Associates 334 Patents Granted 1.7 Billion+ Devices Manufacturing Capacity Per year 6
Slide 8: Navigating the Path
Navigating the Path Building Tomorrow’s Healthcare Solutions Started In 2028 1997 2002-09 2011-19 2020-24 2025 - 27 & beyond Commencement Product and facility New R&D Center, of Manufacturing expansion Acq of Plan 1 Health, Operation New Manufacturing › Launched › Prioritize the › Through a Plants d
Slide 9: Way Forward
Way Forward Research & Development § Targeted R&D investments towards transformative therapeutic areas, aiming towards innovations Emphasizing Inorganic Growth § Integration of AI and IoT technologies to enhance efficiency & precision Strategic Alliances to foster synergies and expanding market reac
Slide 10: Q3 and 9M Financial Performance Summary
Agenda Q3 and 9M Financial Performance Summary
Slide 11: YoY Performance Summary Q3 FY 25
YoY Performance Summary Q3 FY 25 Figs in Rs. Crs unless specified Consolidated Consolidated Consolidated Consolidated RoCE* Revenue EBITDA EBITDA % PAT 424.2 116.3 27.4% 85.2 24.9% 27.9% 31.1% 23.9% 63BPS 339.6 90.9 26.8% 65.0 # of Devices Sold Increase in Sales Net Cash # of Patents (units in crs)
Slide 12: YoY Performance Summary 9M FY 25
YoY Performance Summary 9M FY 25 Figs in Rs. Crs unless specified Consolidated Consolidated Consolidated Consolidated RoCE* Revenue EBITDA EBITDA % PAT 1229.0 336.7 27.4% 246.7 23.2% 27.6% 23.9% 95BPS 29.9% 997.7 263.9 26.5% 189.9 # of Devices Sold Increase in Sales Net Cash # Patents (units in crs)
Slide 13: Key Updates for the Quarter
Key Updates for the Quarter • Received regulatory approval for Drug Eluting Stent; commercialization expected soon. • Signed JV agreement with AMPIN to set up a 9.9MW Solar power plant at Sirsa, Haryana; PML’s investment commitment of Rs. 3.6crs Key • Ground -breaking ceremony held at Palwal plant;
Slide 14: Consolidated Financial Performance Summary
Consolidated Financial Performance Summary Figs in Rs. Crs unless specified Particulars Q3 FY 25 Q3 FY 24 Growth % 9M FY 25 9M FY 24 Growth % Revenue from Operations 424.2 339.6 24.9% 1229.0 997.7 23.2% Cost of Good Sold 146.5 118.0 24.1% 407.3 351.4 15.9% Gross Profit 277.7 221.6 25.3% 821.7 646.3
Slide 15: Standalone Financial Performance Summary
Standalone Financial Performance Summary Figs in Rs. Crs unless specified Particulars Q3 FY 25 Q3 FY 24 Growth % 9M FY 25 9M FY 24 Growth % Revenue from Operations 410.9 320.9 28.1% 1180.8 946.3 24.8% Cost of Good Sold 140.2 111.0 26.3% 387.9 328.7 18.0% Gross Profit 270.7 209.8 29.0% 793.0 617.6 28
Slide 16: Standalone Sales Financial Performance Analysis
Standalone Sales Financial Performance Analysis Figs in Rs. Crs unless specified Particulars Q3 FY 25 Q3 FY 24 Growth % 9M FY 25 9M FY 24 Growth % Domestic Revenue 126.1 101.9 23.8% 351.4 301.2 16.7% Exports Revenue 284.8 218.9 30.1% 829.5 645.1 28.6% Total Operating Revenue 410.9 320.9 28.1% 1180.8
Slide 17: Segment Wise Sales Performance Analysis
Segment Wise Sales Performance Analysis Figs in Rs. Crs unless specified Particulars Q3 FY 25 Q3 FY 24 Growth % 9M FY 25 9M FY 24 Growth % Infusion Therapy 267.1 214.2 24.7% 800.3 639.7 25.1% Renal 38.0 25.3 50.4% 104.6 66.9 56.4% Others 105.8 81.4 30.0% 276.0 239.8 15.1% Total Operating Revenue 411
Slide 18: Return Ratios Basis Standalone Financials
Return Ratios Basis Standalone Financials ROCE ROE * 30.0% 20.0% 18.7% 18.8% * 25.0% 23.0% 23.9% 15.5% 15.0% 14.4% 20.0% 18.9% 17.4% 15.0% 10.0% 10.0% 5.0% 5.0% 0.0% 0.0% FY 22 FY 23 FY 24 Dec'24 FY 22 FY 23 FY 24 Dec'24 *Excludes the amount raised through QIP in August 2024, EBIT has been computed
Slide 19: Thank You
Thank You For any investor related queries reach us at: rahul.gautam@polymedicure.com